688278 特宝生物
已收盘 12-19 15:00:01
资讯
新帖
简况
特宝生物（688278）发布取消监事会及修订公司章程公告，12月18日股价下跌0.71%
证券之星 · 12-18 22:36
特宝生物（688278）发布取消监事会及修订公司章程公告，12月18日股价下跌0.71%
12月17日特宝生物发生1笔大宗交易 成交金额270.67万元
证券之星 · 12-17 17:50
12月17日特宝生物发生1笔大宗交易 成交金额270.67万元
特宝生物（688278）披露召开2025年第一次临时股东大会通知，12月2日股价上涨0.41%
证券之星 · 12-02
特宝生物（688278）披露召开2025年第一次临时股东大会通知，12月2日股价上涨0.41%
特宝生物：截至2025年9月30日，公司股东人数为8608户
证券日报 · 11-25
特宝生物：截至2025年9月30日，公司股东人数为8608户
每周股票复盘：特宝生物（688278）捐赠超4万支药品及现金
证券之星 · 11-23
每周股票复盘：特宝生物（688278）捐赠超4万支药品及现金
特宝生物（688278）披露公司章程（2025年11月修订），11月17日股价下跌2.2%
证券之星 · 11-17
特宝生物（688278）披露公司章程（2025年11月修订），11月17日股价下跌2.2%
每周股票复盘：特宝生物（688278）派格宾新增适应症获国家药监局批准
证券之星 · 11-09
每周股票复盘：特宝生物（688278）派格宾新增适应症获国家药监局批准
股市必读：特宝生物（688278）11月5日披露最新机构调研信息
证券之星 · 11-06
股市必读：特宝生物（688278）11月5日披露最新机构调研信息
股市必读：10月31日特宝生物现423.46万元大宗交易
证券之星 · 11-03
股市必读：10月31日特宝生物现423.46万元大宗交易
每周股票复盘：特宝生物（688278）派格宾适应症获批推动临床治愈认知
证券之星 · 11-02
每周股票复盘：特宝生物（688278）派格宾适应症获批推动临床治愈认知
特宝生物（688278）披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果，10月27日股价下跌0.96%
证券之星 · 10-27
特宝生物（688278）披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果，10月27日股价下跌0.96%
每周股票复盘：特宝生物（688278）Q3营收增26.85%
证券之星 · 10-26
每周股票复盘：特宝生物（688278）Q3营收增26.85%
国金证券：给予特宝生物买入评级
证券之星 · 10-24
国金证券：给予特宝生物买入评级
股市必读：特宝生物(688278)股东户数0.86万户，较上期增加2%
证券之星 · 10-24
股市必读：特宝生物(688278)股东户数0.86万户，较上期增加2%
特宝生物(688278.SH)发布前三季度业绩，归母净利润6.66亿元，同比增长20.21%
智通财经 · 10-22
特宝生物(688278.SH)发布前三季度业绩，归母净利润6.66亿元，同比增长20.21%
10月22日特宝生物发生1笔大宗交易 成交金额1799.78万元
证券之星 · 10-22
10月22日特宝生物发生1笔大宗交易 成交金额1799.78万元
每周股票复盘：特宝生物（688278）派格宾新增适应症获准上市
证券之星 · 10-19
每周股票复盘：特宝生物（688278）派格宾新增适应症获准上市
10月14日特宝生物现376.04万元大宗交易
证券之星 · 10-14
10月14日特宝生物现376.04万元大宗交易
国金证券：给予特宝生物买入评级
证券之星 · 10-13
国金证券：给予特宝生物买入评级
特宝生物(688278.SH)：派格宾增加适应症上市许可申请获得批准
智通财经 · 10-12
特宝生物(688278.SH)：派格宾增加适应症上市许可申请获得批准
暂无数据
公司概况
公司名称：
厦门特宝生物工程股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-17
主营业务：
厦门特宝生物工程股份有限公司的主营业务是重组蛋白质及其长效修饰药物研发、生产和销售。公司的主要产品是派格宾、益佩生、珮金、特尔立、特尔津、特尔康、愈适达。公司产品荣膺国家重大新药创制科技重大专项成果，成功入选“2023年度中国医药生物技术十大进展”，获评“2024年度药物创新成就奖”。
发行价格：
8.24
{"stockData":{"symbol":"688278","market":"SH","secType":"STK","nameCN":"特宝生物","latestPrice":85,"timestamp":1766127601000,"preClose":82.95,"halted":0,"volume":2185985,"delay":0,"changeRate":0.0247,"floatShares":408000000,"shares":408000000,"eps":2.3019,"marketStatus":"已收盘","change":2.05,"latestTime":"12-19 15:00:01","open":82.78,"high":85.57,"low":82.78,"amount":185000000,"amplitude":0.0336,"askPrice":85,"askSize":17,"bidPrice":84.99,"bidSize":5,"shortable":0,"etf":0,"ttmEps":2.3019,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":82.95,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":91.25,"lowLimit":74.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":408189480,"isCdr":false,"pbRate":11.53,"roa":"--","peRate":36.926018,"roe":"23.82%","epsLYR":2.03,"committee":-0.76,"marketValue":34696000000,"turnoverRate":0.0054,"status":0,"afterMarket":{"amount":0,"volume":0,"close":85,"buyVolume":0,"sellVolume":0,"time":1766129637768,"indexStatus":"已收盘 12-19 15:30:00","preClose":82.95},"floatMarketCap":34696000000},"requestUrl":"/m/hq/s/688278/tweets","defaultTab":"tweets","newsList":[{"id":"2592390265","title":"特宝生物（688278）发布取消监事会及修订公司章程公告，12月18日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592390265","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592390265?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:36","pubTimestamp":1766068584,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，特宝生物报收于82.95元，较前一交易日下跌0.71%，最新总市值为338.59亿元。该股当日开盘83.12元，最高84.75元，最低82.28元，成交额达1.12亿元，换手率为0.33%。近日，厦门特宝生物工程股份有限公司召开2025年第一次临时股东大会，审议通过了《关于取消监事会、修订<公司章程>的议案》及多项公司治理制度修订议案，包括股东会议事规则、董事会议事规则、独立董事制度等。出席会议的股东及代理人共71人，代表有表决权股份总数的27.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800039168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2592699542","title":"12月17日特宝生物发生1笔大宗交易 成交金额270.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592699542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592699542?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:50","pubTimestamp":1765965025,"startTime":"0","endTime":"0","summary":"证券之星消息，12月17日特宝生物发生大宗交易，交易数据如下：大宗交易成交价格83.54元，成交3.24万股，成交金额270.67万元，买方营业部为国泰海通证券股份有限公司总部，卖方营业部为广发证券股份有限公司厦门湖滨南路证券营业部。近三个月该股共发生9笔大宗交易，合计成交8589.0手。该股近期无解禁股上市。截至2025年12月17日收盘，特宝生物报收于83.54元，上涨0.29%，换手率0.31%，成交量1.27万手，成交额1.06亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700028363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2588846051","title":"特宝生物（688278）披露召开2025年第一次临时股东大会通知，12月2日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588846051","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588846051?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:30","pubTimestamp":1764685840,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，特宝生物报收于80.33元，较前一交易日上涨0.41%，最新总市值为327.9亿元。近日，特宝生物发布关于召开2025年第一次临时股东大会的通知。公告显示，厦门特宝生物工程股份有限公司将于2025年12月18日召开2025年第一次临时股东大会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。股权登记日为2025年12月11日，登记时间截至2025年12月17日16时。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200040058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2586478324","title":"特宝生物：截至2025年9月30日，公司股东人数为8608户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478324","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586478324?lang=zh_cn&edition=full","pubTime":"2025-11-25 19:33","pubTimestamp":1764070380,"startTime":"0","endTime":"0","summary":"证券日报网讯特宝生物11月25日在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东人数为8608户。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-25/doc-infyrmiy2944170.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-25/doc-infyrmiy2944170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688278","BK0239"],"gpt_icon":0},{"id":"2585055411","title":"每周股票复盘：特宝生物（688278）捐赠超4万支药品及现金","url":"https://stock-news.laohu8.com/highlight/detail?id=2585055411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585055411?lang=zh_cn&edition=full","pubTime":"2025-11-23 03:29","pubTimestamp":1763839749,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，特宝生物报收于78.36元，较上周的77.86元上涨0.64%。本周关注点公司公告汇总：特宝生物向基金会捐赠不超过4万支益佩生及66.16万元现金。公司公告汇总特宝生物：关于对外捐赠的公告厦门特宝生物工程股份有限公司于2025年11月17日召开第九届董事会第十四次会议，审议通过对外捐赠议案。最近十二个月内，公司累计对外捐赠金额为8,115.54万元。公司股本总数由40,680万股变更为40,818.948万股，注册资本由40,680万元变更为40,818.948万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"gpt_icon":0},{"id":"2584962115","title":"特宝生物（688278）披露公司章程（2025年11月修订），11月17日股价下跌2.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584962115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584962115?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:19","pubTimestamp":1763389146,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，特宝生物报收于76.15元，较前一交易日下跌2.2%，最新总市值为310.84亿元。该股当日开盘77.68元，最高77.86元，最低74.8元，成交额达1.25亿元，换手率为0.4%。公司近日发布公告称，厦门特宝生物工程股份有限公司章程于2025年11月进行修订。根据公告，公司为永久存续的股份有限公司，注册资本为人民币40,818.948万元，股票在上海证券交易所上市。公司设董事会由9名董事组成，监事会由3名监事组成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700036942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2582586120","title":"每周股票复盘：特宝生物（688278）派格宾新增适应症获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2582586120","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582586120?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:22","pubTimestamp":1762633333,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，特宝生物报收于73.08元，较上周的73.01元上涨0.1%。本周，特宝生物11月3日盘中最高价报75.86元。本周关注点来自机构调研要点：派格宾联合核苷（酸）类似物用于慢乙肝患者HBsAg持续清除的新增适应症获国家药监局批准。此外，2024年7月，派格宾新增适应症“原发性血小板增多症”获得药物临床试验批准，目前该临床试验正有序开展。公司产品派格宾、珮金、特尔立、特尔津、特尔康已进入国家医疗保险目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"gpt_icon":0},{"id":"2581707107","title":"股市必读：特宝生物（688278）11月5日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2581707107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581707107?lang=zh_cn&edition=full","pubTime":"2025-11-06 01:45","pubTimestamp":1762364718,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，特宝生物报收于74.0元，上涨0.89%，换手率0.41%，成交量1.69万手，成交额1.23亿元。来自机构调研要点：派格宾联合核苷（酸）类似物用于慢乙肝患者HBsAg持续清除的新增适应症已于2025年10月获国家药监局批准，为国内首个获批该适应症的药品。派格宾新增适应症“原发性血小板增多症”于2024年7月获临床试验批准，目前临床试验正有序开展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600001171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2580235640","title":"股市必读：10月31日特宝生物现423.46万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2580235640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580235640?lang=zh_cn&edition=full","pubTime":"2025-11-03 03:44","pubTimestamp":1762112656,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，特宝生物报收于73.01元，上涨3.11%，换手率0.66%，成交量2.7万手，成交额1.95亿元。来自交易信息汇总：当日特宝生物发生423.46万元大宗交易。交易信息汇总资金流向10月31日主力资金净流出1717.21万元，占总成交额8.82%；游资资金净流入447.37万元，占总成交额2.3%；散户资金净流入1269.84万元，占总成交额6.52%。大宗交易10月31日特宝生物现423.46万元大宗交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300000787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"gpt_icon":0},{"id":"2580479120","title":"每周股票复盘：特宝生物（688278）派格宾适应症获批推动临床治愈认知","url":"https://stock-news.laohu8.com/highlight/detail?id=2580479120","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580479120?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:31","pubTimestamp":1762029068,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，特宝生物报收于73.01元，较上周的71.69元上涨1.84%。来自机构调研要点：派格宾新增慢乙肝临床治愈适应症获批，标志乙肝治疗目标迈向表面抗原持续清除阶段。股本股东变化特宝生物2024年限制性股票激励计划首次授予部分第一个归属期完成，共向600名激励对象归属1,389,480股，股票来源为定向发行A股普通股，上市流通日为2025年10月30日。公司总股本由406,800,000股增至408,189,480股，本次归属不导致实际控制人变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2578864085","title":"特宝生物（688278）披露2024年限制性股票激励计划首次授予部分第一个归属期归属结果，10月27日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578864085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578864085?lang=zh_cn&edition=full","pubTime":"2025-10-27 22:19","pubTimestamp":1761574773,"startTime":"0","endTime":"0","summary":"截至2025年10月27日收盘，特宝生物报收于71.0元，较前一交易日下跌0.96%，最新总市值为288.83亿元。该股当日开盘72.12元，最高72.69元，最低70.78元，成交额达2.34亿元，换手率为0.81%。近日，特宝生物发布《2024年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上市公告》。公告显示，公司2024年限制性股票激励计划首次授予部分第一个归属期归属已完成，共向600名激励对象归属1,389,480股，股票来源为定向发行A股普通股，上市流通日为2025年10月30日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700036349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2578507093","title":"每周股票复盘：特宝生物（688278）Q3营收增26.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578507093","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578507093?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:18","pubTimestamp":1761423491,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，特宝生物报收于71.69元，较上周的77.65元下跌7.68%。本周，特宝生物10月21日盘中最高价报78.99元。股本股东变化：截至2025年9月30日，公司股东户数为8608.0户，较6月30日增加2.0%。业绩披露要点：2025年前三季度营业收入2,479,547,947.46元，同比增长26.85%。交易信息汇总10月22日特宝生物发生1笔大宗交易，成交金额1799.78万元。研发投入合计311,840,338.05元，同比增长38.53%，研发投入占营业收入的比例为12.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278"],"gpt_icon":0},{"id":"2577999556","title":"国金证券：给予特宝生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2577999556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577999556?lang=zh_cn&edition=full","pubTime":"2025-10-24 08:31","pubTimestamp":1761265903,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,马居东近期对特宝生物进行研究并发布了研究报告《新品推广费用承压，治愈适应症催化有待体现》，给予特宝生物买入评级。公司怡培生长激素注射液于2025年5月29日正式获得国家药品监督管理局批准上市，用于治疗3岁及以上儿童的生长激素缺乏症所致的生长缓慢。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为101.39。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400007161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278"],"gpt_icon":0},{"id":"2577958215","title":"股市必读：特宝生物(688278)股东户数0.86万户，较上期增加2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577958215","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577958215?lang=zh_cn&edition=full","pubTime":"2025-10-24 01:15","pubTimestamp":1761239709,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘，特宝生物报收于72.62元，下跌6.07%，换手率1.48%，成交量6.01万手，成交额4.38亿元。股本股东变化股东户数变动近日特宝生物披露，截至2025年9月30日公司股东户数为8608.0户，较6月30日增加169.0户，增幅为2.0%。公司公告汇总特宝生物：2025年第三季度报告二、股东信息报告期末普通股股东总数为8,608户。截至2025年9月30日，股东杨银祥持有公司股份3,501,834股，全部通过信用证券账户持有。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400001228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"gpt_icon":0},{"id":"2577036505","title":"特宝生物(688278.SH)发布前三季度业绩，归母净利润6.66亿元，同比增长20.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577036505","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577036505?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:19","pubTimestamp":1761131974,"startTime":"0","endTime":"0","summary":"智通财经APP讯，特宝生物(688278.SH)披露2025年第三季度报告，公司前三季度实现营收24.8亿元，同比增长26.85%;归属于上市公司股东的净利润6.66亿元，同比增长20.21%;扣非净利润6.73亿元，同比增长15.91%;基本每股收益1.64元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"特宝生物(688278.SH)发布前三季度业绩，归母净利润6.66亿元，同比增长20.21%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688278"],"gpt_icon":0},{"id":"2577352945","title":"10月22日特宝生物发生1笔大宗交易 成交金额1799.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577352945","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577352945?lang=zh_cn&edition=full","pubTime":"2025-10-22 17:31","pubTimestamp":1761125462,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日特宝生物发生大宗交易，交易数据如下：大宗交易成交价格77.31元，成交23.28万股，成交金额1799.78万元，买方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部，卖方营业部为广发证券股份有限公司厦门湖滨南路证券营业部。近三个月该股共发生11笔大宗交易，合计成交1.14万手。该股近期无解禁股上市。截至2025年10月22日收盘，特宝生物报收于77.31元，下跌1.58%，换手率0.43%，成交量1.75万手，成交额1.36亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200027955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2576273044","title":"每周股票复盘：特宝生物（688278）派格宾新增适应症获准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2576273044","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576273044?lang=zh_cn&edition=full","pubTime":"2025-10-19 05:24","pubTimestamp":1760822655,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，特宝生物报收于77.65元，较上周的81.52元下跌4.75%。来自公司公告汇总：派格宾联合用药用于慢性乙肝患者HBsAg持续清除的适应症获国家药监局批准。公司公告汇总厦门特宝生物工程股份有限公司近日收到国家药品监督管理局核准签发的《药品注册证书》，公司产品派格宾联合核苷（酸）类似物用于成人慢性乙型肝炎患者HBsAg持续清除的增加适应症上市许可申请获得批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900001215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688278"],"gpt_icon":0},{"id":"2575298150","title":"10月14日特宝生物现376.04万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2575298150","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575298150?lang=zh_cn&edition=full","pubTime":"2025-10-14 17:26","pubTimestamp":1760433966,"startTime":"0","endTime":"0","summary":"证券之星消息，10月14日特宝生物发生大宗交易，交易数据如下：大宗交易成交价格80.92元，成交4.65万股，成交金额376.04万元，买方营业部为国泰海通证券股份有限公司总部，卖方营业部为广发证券股份有限公司厦门湖滨南路证券营业部。近三个月该股共发生11笔大宗交易，合计成交9754.0手。该股近期无解禁股上市。截至2025年10月14日收盘，特宝生物报收于80.92元，下跌3.54%，换手率0.83%，成交量3.36万手，成交额2.76亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400054245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278","BK0239"],"gpt_icon":0},{"id":"2575449190","title":"国金证券：给予特宝生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2575449190","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575449190?lang=zh_cn&edition=full","pubTime":"2025-10-13 08:15","pubTimestamp":1760314530,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,马居东近期对特宝生物进行研究并发布了研究报告《派格宾新适应症获批，基石地位进一步巩固》，给予特宝生物买入评级。 经营分析 HBsAg持续清除为治愈标志，派格宾为首个获批该适应症药品。全国约有7500万慢性乙型肝炎感染者，慢性乙肝会大幅增加患者未来罹患肝衰竭、肝硬化和肝癌的风险。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为101.39。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300002422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688278"],"gpt_icon":0},{"id":"2574649919","title":"特宝生物(688278.SH)：派格宾增加适应症上市许可申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2574649919","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574649919?lang=zh_cn&edition=full","pubTime":"2025-10-12 16:22","pubTimestamp":1760257366,"startTime":"0","endTime":"0","summary":"智通财经APP讯，特宝生物(688278.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药品注册证书》，公司产品派格宾联合核苷(酸)类似物用于成人慢性乙型肝炎患者的HBsAg持续清除的增加适应症(简称“增加适应症”)上市许可申请获得批准。派格宾是公司目前的核心产品，是公司自主研发的全球首个40kD聚乙二醇长效干扰素α-2b注射液，是治疗用生物制品国家1类新药，是我国第一个国产上市的聚乙二醇(PEG)修饰干扰素品种。派格宾于2016年10月获批上市，获批适应症为治疗成人慢性丙型肝炎;2017年9月获批成人慢性乙型肝炎适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"特宝生物(688278.SH)：派格宾增加适应症上市许可申请获得批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688278"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766155361348,"stockEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":0.0762},{"period":"3month","weight":0.0484},{"period":"6month","weight":0.2088},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1401}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"厦门特宝生物工程股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8608人(较上一季度增加2.00%)","perCapita":"47419股","listingDate":"2020-01-17","address":"福建省厦门市海沧区新阳工业区翁角路330号","registeredCapital":"40818万元","survey":" 厦门特宝生物工程股份有限公司的主营业务是重组蛋白质及其长效修饰药物研发、生产和销售。公司的主要产品是派格宾、益佩生、珮金、特尔立、特尔津、特尔康、愈适达。公司产品荣膺国家重大新药创制科技重大专项成果，成功入选“2023年度中国医药生物技术十大进展”，获评“2024年度药物创新成就奖”。","listedPrice":8.24},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"特宝生物(688278)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供特宝生物(688278)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"特宝生物,688278,特宝生物股票,特宝生物股票老虎,特宝生物股票老虎国际,特宝生物行情,特宝生物股票行情,特宝生物股价,特宝生物股市,特宝生物股票价格,特宝生物股票交易,特宝生物股票购买,特宝生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"特宝生物(688278)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供特宝生物(688278)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}